MyoKardia Inc - Company & Market Research Reports

MyoKardia is a clinical stage biopharmaceutical company that develops therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

From
From
From
From
From
From
From
Myokardia Inc - Product Thumbnail Image

Myokardia Inc

  • Company Profile
  • 65 Pages
Loading Indicator
adroll